Colleen Niswender Archives
Drug discovery efforts may lead to new Rett syndrome treatments
Aug. 24, 2017—Vanderbilt University research-ers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit.
Vanderbilt begins Phase 1 trials of new Alzheimer’s drug
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
VUMC’s Rett Syndrome Clinic lands national recognition
Nov. 17, 2016—Vanderbilt’s Rett Syndrome Clinic has been named a Rett Syndrome Clinical Research Center of Excellence by Rettsyndrome.org.
Study reveals possible ‘dimmer switch’ drug for Rett syndrome
Mar. 3, 2016—Researchers at Vanderbilt University Medical Center have relieved symptoms in a mouse model of Rett syndrome with a drug-like compound that works like the dimmer switch in an electrical circuit.
Autism Speaks grant boosts Rett syndrome research
Jan. 23, 2014—Colleen Niswender, Ph.D., research associate professor of Pharmacology, has received a three-year, $450,000 grant from the autism science and advocacy organization Autism Speaks to support studies investigating a possible new treatment for Rett syndrome.
Drug-like molecules aimed at improving treatment of Parkinson’s
Sep. 30, 2011—Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects.
Neuroscience drug discovery center opens at Vanderbilt
Mar. 11, 2011—Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain.
